Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Beginning Cash Position: ¥727 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688076 Sinopep Allsino Bio Pharmaceutical Co Ltd SHSE:688076
75 GF Score
Price ¥27.56
GF Value ¥54.05
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Sinopep Allsino Bio Pharmaceutical Co Beginning Cash Position?

Sinopep Allsino Bio Pharmaceutical Co SHSE:688076 +0.29% 75 Beginning Cash Position is ¥727 Mil as of Jun. 2026. GuruFocus rates SHSE:688076 with a GF Score™ of 75/100 and a GF Value™ of ¥54.05 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Sinopep Allsino Bio Pharmaceutical Co's Beginning Cash Position for the quarter that ended in Jun. 2026 was ¥727 Mil.

Sinopep Allsino Bio Pharmaceutical Co's quarterly Beginning Cash Position declined from Dec. 2025 (¥830 Mil) to Mar. 2026 (¥802 Mil) and declined from Mar. 2026 (¥802 Mil) to Jun. 2026 (¥727 Mil).

Sinopep Allsino Bio Pharmaceutical Co's annual Beginning Cash Position increased from Dec. 2023 (¥361 Mil) to Dec. 2024 (¥678 Mil) but then declined from Dec. 2024 (¥678 Mil) to Dec. 2025 (¥493 Mil).

Sinopep Allsino Bio Pharmaceutical Co Beginning Cash Position Related Terms

Sinopep Allsino Bio Pharmaceutical Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Sinopep Allsino Bio Pharmaceutical Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopep Allsino Bio Pharmaceutical Co Beginning Cash Position Chart

Sinopep Allsino Bio Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.07 545.20 360.85 677.53 492.55

Sinopep Allsino Bio Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 562.96 504.51 829.93 802.01 726.60
SHSE:688076
75GF Score
Sinopep Allsino Bio Pharmaceutical Co Ltd SHSE:688076
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopep Allsino Bio Pharmaceutical Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of ¥727 Mil mean?
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) has a Beginning Cash Position of ¥727 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors.
Is Sinopep Allsino Bio Pharmaceutical Co's Beginning Cash Position too high?
Sinopep Allsino Bio Pharmaceutical Co's current Beginning Cash Position is ¥727 Mil. Overall, Sinopep Allsino Bio Pharmaceutical Co has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopep Allsino Bio Pharmaceutical Co's Beginning Cash Position compare to VRTX and REGN?
Sinopep Allsino Bio Pharmaceutical Co's Beginning Cash Position of ¥727 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors. Sinopep Allsino Bio Pharmaceutical Co's current Beginning Cash Position is ¥727 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopep Allsino Bio Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥54.05, compared to a current price of ¥27.56 — trading 49% below its estimated fair value. The current Beginning Cash Position is ¥727 Mil. Sinopep Allsino Bio Pharmaceutical Co's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076), the current Beginning Cash Position is ¥727 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥27.56 is trading 49% below its estimated GF Value™ of ¥54.05. GuruFocus considers Sinopep Allsino Bio Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:688076:

  • Beginning Cash Position: ¥727 Mil
  • GF Value™: ¥54.05 vs. price of ¥27.56 (49% below fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688076 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopep Allsino Bio Pharmaceutical Co Business Description

Address No. 28, Linpu Road, Economic and Technological Development Zone, Jiangsu Province, Lianyungang, CHN, 222069
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
75GF Score

Get the complete analysis for SHSE:688076

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.56
Price
¥54.05
GF Value